Date | Price Target | Rating | Analyst |
---|---|---|---|
7/18/2024 | $14.00 | Outperform | Oppenheimer |
11/15/2023 | $4.00 → $11.00 | Hold → Buy | Jefferies |
10/26/2023 | $4.00 → $8.00 | Underweight → Equal-Weight | Morgan Stanley |
6/21/2023 | Outperform | Evercore ISI | |
6/12/2023 | $9.00 | Buy | Guggenheim |
3/17/2023 | $6.00 | Outperform | SVB Securities |
8/12/2022 | $10.00 → $5.00 | Overweight → Underweight | Morgan Stanley |
6/17/2022 | $19.00 | Outperform | BMO Capital Markets |
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen
BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a
Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.
SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned for 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody BOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceuti
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational feeder study Dosing subjects in ongoing Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumorsConducting IND enabling activities for ORX750, an orally administered, selective orexin receptor 2 (OX2R) agonist, with the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders; ORX750 profile to be presented at scientific meeting in 2023 BOSTON and LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals
Oppenheimer analyst Francois Brisebois initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform rating and announces Price Target of $14.
Morgan Stanley analyst Matthew Harrison maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Equal-Weight and raises the price target from $8 to $11.
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024.
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares ("ADSs"), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The off
BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares ("ADSs"), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whethe
2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT)Favorable safety and tolerability profile with no observations of frequently reported on-target adverse events (AEs) associated with other OX2R agonists, visual disturbances or hepatotoxicity as of the data cutoff date 1PK profile supports once-daily dosing Company plans to rapidly initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) BOSTON and LONDON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
424B5 - Centessa Pharmaceuticals plc (0001847903) (Filer)
8-K - Centessa Pharmaceuticals plc (0001847903) (Filer)
424B5 - Centessa Pharmaceuticals plc (0001847903) (Filer)
Oppenheimer initiated coverage of Centessa Pharmaceuticals with a rating of Outperform and set a new price target of $14.00
Jefferies upgraded Centessa Pharmaceuticals from Hold to Buy and set a new price target of $11.00 from $4.00 previously
Morgan Stanley upgraded Centessa Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $8.00 from $4.00 previously